Please select the option that best describes you:
In a patient with HR+HER2+ early breast cancer who is receiving adjuvant T-DM1 for residual disease, do you overlap endocrine therapy with T-DM1?
Answer from: Medical Oncologist at Community Practice
Yes, in the KATHERINE trial, endocrine therapy was started concurrent with the T-DM1, same with radiation as indicated. This is included I believe in the published supplement in KATHERINE. So...yes, both endocrine therapy and radiation are fine to start while on T-DM1.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Yes. In the KATHERINE trial, concomitant endocrine therapy was allowed per institutional standard, so I do overlap the ado-trastuzumab with the endocrine therapy chosen for the patient.